The MTHFR story is simultaneously one of the most important and most oversimplified developments in functional medicine. On one side: genuine clinical significance that mainstream medicine chronically underestimates. On the other: an internet ecosystem of fear-mongering, supplement marketing, and wild extrapolation that has turned a real genetic variant into a dramatic diagnosis for everything from autism to cancer. This guide cuts through both.
What MTHFR Actually Does
MTHFR (methylenetetrahydrofolate reductase) is an enzyme that converts folate (vitamin B9) from its dietary form into the active form your cells can use — specifically 5-methyltetrahydrofolate (5-MTHF). This active folate is the key currency of the methylation cycle, a biochemical process that happens approximately one billion times per second in every cell of your body.
Methylation is not a supplement trend. It is a fundamental biochemical process involved in: DNA synthesis and repair, gene expression regulation (the epigenetic layer), neurotransmitter production (dopamine, serotonin, norepinephrine), detoxification in the liver, immune cell production, histamine breakdown, and myelin sheath maintenance in the nervous system.
When this enzyme function is impaired, the methylation cycle runs at reduced efficiency. The consequences are subtle and systemic — which is exactly why they’re easy to miss in conventional medicine. No discrete disease shows up. Just a pattern of suboptimal function across multiple systems.
MTHFR variants don’t cause disease. They create a metabolic environment that makes certain diseases more likely if other conditions — nutritional, environmental, lifestyle — align unfavorably.
The Two Primary Variants: C677T and A1298C
The MTHFR gene has over 50 known variants, but two are clinically relevant for most people: C677T and A1298C. Different mutations at different locations on the gene, with different functional consequences.
C677T is the more studied and more clinically significant variant. The name refers to a substitution at position 677 — cytosine (C) replaced by thymine (T). This creates a thermolabile (heat-sensitive) form of the enzyme that functions at reduced efficiency. Having one copy (heterozygous, written 677CT) reduces enzyme activity by approximately 35%. Having two copies (homozygous, 677TT) reduces activity by approximately 70%. About 10% of the population is homozygous for C677T; roughly 40% carry at least one copy.
A1298C involves a substitution at position 1298 — adenine (A) replaced by cytosine (C). Its functional effects are less dramatic than C677T in isolation. Heterozygous A1298C (1298AC) causes minimal enzyme reduction. Homozygous A1298C (1298CC) reduces activity by approximately 40%. A1298C primarily affects the 5-MTHF to BH4 (tetrahydrobiopterin) conversion, which is relevant for neurotransmitter production specifically.
Compound heterozygosity — having one copy of C677T AND one copy of A1298C — is clinically significant and quite common. Functionally, this combination approximates having two copies of C677T in terms of methylation impairment.
Testing Options: What’s Actually Useful
MTHFR testing has become accessible and inexpensive. Several pathways are available:
23andMe or AncestryDNA test for both C677T and A1298C as part of their raw genome data. The results won’t appear in their consumer reports — the raw data needs to be downloaded and run through a third-party interpreter like Genetic Genie, SelfDecode, or Rhonda Patrick’s genetic tools. The cheapest entry point ($100-200 for the full genome test).
Dedicated MTHFR blood tests are available through most major labs with a physician order. LabCorp and Quest both offer MTHFR mutation analysis panels that test C677T and A1298C directly from blood. Cost: $100-300 depending on insurance.
Comprehensive methylation panels from labs like Genomic Solutions or via practitioners using 3×4 Genetics, StrateGene, or Genomind test the full methylation pathway — not just MTHFR but also COMT, MTR, MTRR, MTHFD1, and other relevant variants. This is the appropriate level of testing if initial MTHFR results are positive and functional markers remain abnormal.
What to test alongside genetics: homocysteine (the most useful functional marker of methylation — elevated homocysteine indicates the pathway is backed up regardless of genotype), RBC folate, serum B12, methylmalonic acid (functional B12 marker), and plasma amino acids if available.
- Homocysteine above 10 µmol/L suggests methylation pathway stress
- Homocysteine above 15 µmol/L is associated with significantly elevated cardiovascular and cognitive risk
- Optimal homocysteine is below 7-8 µmol/L
- Normal homocysteine with MTHFR variants means the body is compensating adequately
- Elevated homocysteine without MTHFR variants suggests B12/B6 deficiency or other pathway issues
What the Variants Actually Increase Risk For
Strong evidence: Cardiovascular disease risk elevation (via homocysteine — this is mechanistically well-understood), neural tube defects in offspring (the original reason MTHFR entered mainstream medicine), recurrent pregnancy loss (especially homozygous C677T), venous thromboembolism risk, and depression/mood disorders (via neurotransmitter synthesis and methylation of monoamine oxidase gene).
Moderate evidence: Increased risk with certain chemotherapy drugs (methotrexate specifically, which works by blocking folate metabolism — MTHFR variants increase toxicity), migraine with aura, and potentially Alzheimer’s disease risk via homocysteine-mediated neurotoxicity.
Weak or contested evidence: Autism spectrum disorder, most cancers, multiple sclerosis, fibromyalgia, chronic fatigue. The internet connects MTHFR to all of these. The actual research is weak, inconsistent, or confounded. Doesn’t mean these connections don’t exist — means the evidence doesn’t support confident clinical decisions based on them yet.
The critical point: Having MTHFR variants increases risk probabilistically and conditionally — conditional on folate/B12 status, dietary habits, lifestyle stress loads, and other gene variants. Two people with identical MTHFR genotypes can have dramatically different health outcomes based on everything else.
Your genotype is a loading condition, not a sentence. Whether it fires depends entirely on the environment — metabolic, nutritional, and psychological — you build around it.
The Folic Acid Problem
This is where the science gets genuinely important and the stakes get real. Folic acid is the synthetic, oxidized form of folate added to fortified foods and found in most cheap supplements. To be usable by the body, folic acid must be converted to the active 5-MTHF form through a multi-step enzymatic process — and MTHFR is a critical enzyme in that conversion.
For people with significant MTHFR impairment, unmetabolized folic acid (UMFA) builds up in the blood. UMFA competes with active methylfolate for folate receptors, potentially blocking folate transport across critical barriers including the blood-brain barrier. Not a theoretical concern — UMFA has been detected in blood samples of people eating folate-fortified foods, and it correlates inversely with natural killer cell function in some studies.
The practical implication: MTHFR C677T (especially homozygous) or compound heterozygosity may make folic acid supplementation not just ineffective but actively counterproductive. This affects prenatal vitamins (most contain folic acid), fortified cereals and bread (mandatory fortification in the US adds folic acid to refined grains), and the vast majority of B-complex supplements.
The alternative: methylfolate (5-MTHF) is the pre-converted, active form. It bypasses the MTHFR enzyme entirely and is immediately usable. Look for it labeled as “methylfolate,” “L-methylfolate,” “5-MTHF,” or by brand names like Deplin (prescription) or Quatrefolic. The range in clinical use is wide — everyday maintenance amounts sit at one end, and the amounts studied for severe deficiency states or as an adjunct in depression treatment sit an order of magnitude above that, under practitioner supervision.
The Beyond-MTHFR Methylation Pathway
MTHFR is the most famous gene in the methylation pathway, but it’s not the only one. Understanding the broader picture prevents tunnel vision on a single variant.
COMT (Catechol-O-methyltransferase) is the gene that breaks down dopamine, epinephrine, and estrogen using methyl groups. COMT Val158Met variants (rs4680) create either faster or slower catecholamine breakdown. Slow COMT (Met/Met) means dopamine lingers longer — better cognitive performance under calm conditions, worse under stress. Fast COMT (Val/Val) means faster breakdown — generally lower dopamine, potentially less anxiety but also less drive. COMT variants interact with MTHFR — understanding both is more useful than either alone.
MTR and MTRR encode methionine synthase and its reductase — the enzymes that use methylfolate to regenerate methionine from homocysteine and maintain B12 function. Variants in these genes can cause functional B12 deficiency even with adequate B12 intake. Particularly relevant when homocysteine remains elevated despite methylfolate supplementation.
CBS (Cystathionine Beta-Synthase) is the enzyme that converts homocysteine into cystathionine, pushing it toward the transsulfuration pathway toward glutathione and taurine. Certain CBS variants cause upregulation of this pathway — homocysteine gets shunted away too quickly, potentially depleting the methyl cycle. This creates a paradox where standard methylation supplements can worsen symptoms.
- Get MTHFR genotype (C677T and A1298C)
- Test functional markers: homocysteine, RBC folate, B12/MMA
- If homocysteine is elevated or symptoms persist, expand to full methylation pathway panel
- Adjust supplementation based on both genotype AND functional markers
- Retest homocysteine 60-90 days after supplementation changes
The RWise MTHFR Response Protocol
Tier 1 — Low impact (heterozygous C677T or A1298C alone, normal homocysteine): Ensure adequate dietary folate from whole foods (leafy greens, legumes). Switch multivitamin to one containing methylfolate instead of folic acid. Avoid excessive unfortified processed food. No dramatic intervention needed. Retest homocysteine annually.
Tier 2 — Moderate impact (compound heterozygous C677T/A1298C or homozygous A1298C, mildly elevated homocysteine 10-15): methylfolate, B12 as methylcobalamin or hydroxocobalamin, B6 as pyridoxal-5-phosphate, and magnesium glycinate. Reduce alcohol (alcohol depletes folate and disrupts methylation). Retest homocysteine at 60 days.
Tier 3 — High impact (homozygous C677T, elevated homocysteine >15, or symptom cluster including mood disorders, fatigue, brain fog, recurrent pregnancy loss): Work with a functional medicine practitioner. L-methylfolate at therapeutic rather than maintenance levels, which requires monitoring. Comprehensive methylation pathway testing. Investigate CBS, COMT, MTR/MTRR variants. Consider organic acid testing for functional pathway assessment.
Pregnancy and MTHFR: The Highest-Stakes Application
Neural tube defects — spina bifida and anencephaly — are among the most well-established consequences of folate insufficiency during early pregnancy. MTHFR variants that impair folate metabolism increase this risk. This is the original reason MTHFR entered mainstream medicine.
The standard recommendation of 400-800 mcg of folic acid daily before and during pregnancy assumes normal MTHFR function. For women with significant MTHFR variants the form matters more than the figure: methylfolate rather than folic acid, since the whole problem is the conversion step. Some practitioners go well above the standard recommendation for homozygous C677T cases planning pregnancy, which is a conversation to have with the practitioner rather than with an article.
Recurrent pregnancy loss — three or more miscarriages — is associated with homozygous MTHFR C677T in multiple studies, likely via both folate insufficiency and increased thrombophilia (clotting tendency). Recurrent pregnancy loss makes MTHFR testing alongside MTHFR-adjacent clotting markers (Factor V Leiden, MTHFR-associated homocysteine elevation) a reasonable investigative step.
Note that methylfolate crosses the placenta more efficiently than folic acid, making it preferable regardless of genotype for women who can tolerate it. Some women with COMT variants experience anxiety or “over-methylation” symptoms on high-dose methylfolate, which is the argument for building up gradually under supervision rather than opening at the top of the range.
FAQ: MTHFR and Genetic Testing
Q: I tested positive for MTHFR variants. Should I panic?
No. MTHFR variants are among the most common genetic variants in the human population — certain variants exist in 40-60% of people. Most people with MTHFR variants live perfectly healthy lives. The variant creates a metabolic tendency, not a destiny. Whether it causes problems depends on how well the methylation pathway is supported through nutrition and lifestyle.
Q: Can I use 23andMe to check my MTHFR status?
Yes. Download the raw data from 23andMe, then upload it to Genetic Genie (geneticgenie.org) for a free methylation report. It will show status for both C677T and A1298C along with other methylation pathway variants. The interpretation quality varies, so use it as a starting point for conversation with a practitioner, not a definitive diagnosis.
Q: My practitioner wants to put me on high-dose methylfolate. Is that safe?
Generally yes, but it requires monitoring. Some people — particularly those with slow COMT variants or sensitivities to methyl donors — experience anxiety, irritability, or mood changes on high-dose methylfolate. If this happens, the fix is usually hydroxocobalamin (which neutralizes excess methyl groups) and dose reduction, not discontinuation.
Q: Does MTHFR affect my risk of heart disease?
Modestly, primarily through the homocysteine mechanism. Elevated homocysteine is an independent cardiovascular risk factor. The clinically relevant point: homocysteine is one of the most responsive biomarkers to supplementation. Getting homocysteine below 8 µmol/L with B-vitamins essentially neutralizes the MTHFR-related cardiovascular risk signal.
Other Clinically Significant SNPs Beyond MTHFR
COMT Val158Met (rs4680) — already mentioned in the methylation context but worth expanding. COMT variants affect not just neurotransmitter clearance but estrogen metabolism. Slow COMT reduces the clearance of catechol estrogens, potentially increasing breast tissue exposure to estrogen metabolites. Particularly relevant for women with estrogen-sensitive conditions (endometriosis, fibroids, estrogen receptor-positive breast cancer history) who carry slow COMT variants. The intervention: ensure adequate methylation support (methylfolate, methylcobalamin), consider DIM (diindolylmethane) to support estrogen phase I metabolism, reduce catecholamine load through stress management.
APOE4 is the most studied genetic Alzheimer’s risk variant. APOE4 carriers (roughly 25% of the population has one copy; 2-3% has two copies) show impaired brain lipid transport and accelerated amyloid accumulation. Having one APOE4 copy triples lifetime Alzheimer’s risk; two copies increases it roughly 10-12 fold. The intervention landscape for APOE4 carriers is evidence-based and actionable: lower saturated fat intake (APOE4 impairs saturated fat clearance via LDL pathway), DHA omega-3 at higher doses, sleep quality prioritization, aggressive cardiovascular risk reduction, and ketogenic diet evidence is mixed but intriguing for APOE4 specifically.
BRCA1/BRCA2 are the breast and ovarian cancer risk genes most people have heard of. Significant pathogenic BRCA variants substantially increase lifetime cancer risk and warrant genetic counseling and medical surveillance protocols beyond the scope of this guide. These are in a different category from MTHFR-type variants — they require specialist medical management, not nutritional optimization.
FTO (fat mass and obesity associated gene) is the most replicated obesity-risk gene. The rs9939609 variant is associated with a 1.7-pound higher average body weight per allele and increased satiety hormone dysregulation. FTO carriers don’t automatically become overweight — the variant creates a tendency toward higher caloric intake via altered satiety signaling, which is modified by diet composition and exercise. Evidence suggests high-intensity exercise more effectively neutralizes FTO’s effect than moderate exercise.
Interpreting Polygenic Scores vs. Single SNPs
The MTHFR conversation focuses on single nucleotide polymorphisms — individual genetic variants with characterized functional effects. Appropriate for high-impact variants with known mechanisms. But modern genomics has revealed that most complex traits — cardiovascular disease risk, cognitive ability, metabolic efficiency, longevity — are not driven by a few large-effect variants but by thousands of small-effect variants acting together.
Polygenic risk scores (PRS) aggregate the effects of thousands of variants into a single risk number. PRS for cardiovascular disease, for example, is now more predictive than most individual clinical risk factors. Companies like Genomics plc (via their Genomics England partnership) and some US direct-to-consumer genetic testing services are beginning to offer PRS for major disease categories.
The practical implication: for common complex diseases, MTHFR status tells you about one metabolic pathway. A polygenic cardiovascular risk score tells you about overall genetic predisposition across dozens of biological pathways. Both are useful. They answer different questions and should guide different interventions.
For most people taking a first step into genetic health testing, the hierarchy is: start with MTHFR (high clinical utility, cheap, clear interventions), then APOE if cognitive aging is a concern, then consider COMT and other methylation pathway variants if symptoms persist despite MTHFR optimization, then polygenic risk scores for disease categories most relevant to family history.
The Ethical Dimensions of Genetic Self-Knowledge
Genetic testing creates information you can’t un-know. For most variants discussed in this guide — MTHFR, COMT, FTO — this is almost entirely positive. The information is actionable, the interventions are within your control, and knowing reduces anxiety by replacing uncertainty with a specific, addressable target.
APOE4 status creates a more complex psychological landscape. Learning of two APOE4 alleles meaningfully changes lifetime Alzheimer’s probability. For some people, this information motivates aggressive preventive action — better sleep, cardiovascular optimization, DHA supplementation, early intervention if cognitive symptoms emerge. For others, it creates anxiety without a clear clinical pathway. Pre-test genetic counseling is genuinely valuable here — not as gatekeeping, but as preparation for what’s about to be learned and how it’ll be used.
BRCA testing has specific insurance implications in the US — genetic discrimination protections under GINA (Genetic Information Nondiscrimination Act) cover health and employment but explicitly exclude life insurance and long-term care insurance. Anyone with significant BRCA variants should consider their insurance situation before testing if these policies aren’t already in place.
For the MTHFR-class variants that are the core of this guide: the information is valuable, the interventions are dietary and supplemental, the downside risk of knowing is minimal, and the upside of addressing the variant is real. Test with confidence. The map isn’t the territory — genotype creates probabilities, not destinies — but navigating with a better map consistently produces better outcomes.
Your genetics describe the terrain you’re navigating. They don’t determine whether you make it across.
Implementing a Methylation Support Protocol Step by Step
The gap between knowing about MTHFR variants and successfully implementing a methylation support protocol is where most people get lost. The theory is clear; the implementation gets complicated by starting dose sensitivities, supplement interactions, and the highly individual nature of methylation chemistry. Here’s a step-by-step implementation guide.
Step 1 — Test before you supplement. Get the MTHFR genotype (C677T and A1298C at minimum) and functional markers (homocysteine, RBC folate, serum B12, methylmalonic acid). Knowing baseline homocysteine is especially important — it tells you whether the body is compensating adequately for whatever variants are present. MTHFR variants without elevated homocysteine may require less aggressive intervention than variants with elevated homocysteine.
Step 2 — Remove folic acid from your environment. Audit every supplement, multivitamin, prenatal vitamin, fortified food, and protein powder consumed. Eliminate or replace anything containing folic acid for anyone carrying significant MTHFR variants. Read labels: “folate” on a label may still be folic acid under the guise of “B9.” Look specifically for “5-methyltetrahydrofolate,” “methylfolate,” “Metafolin,” or “Quatrefolic” as the form.
Step 3 — Start methylfolate low and go slow. The most common mistake in methylation support: starting at high doses immediately. Some people, particularly those with slow COMT variants or histamine intolerance, experience anxiety, irritability, or insomnia when they begin methylfolate. The low-and-slow approach holds at the bottom of the range for two to four weeks before going anywhere. If symptoms show up, the move is to back off rather than stop outright — some methylfolate is still needed — and climb more gradually from there.
Step 4 — Add the cofactors. Methylation doesn’t happen from methylfolate alone. The cycle requires B12 (as methylcobalamin or hydroxocobalamin), B6 (as P5P, which avoids the sensory neuropathy risk that comes with very high-dose pyridoxine), magnesium in the glycinate form, and riboflavin — B2 is required for MTHFR enzyme function and can partially compensate for a reduced-function variant, which is one of the more useful and least discussed facts in this whole area. Zinc supports methionine synthase activity.
Step 5 — Retest homocysteine at 60-90 days. Homocysteine is the feedback metric. Down from 14 to 8? The protocol is working. Unchanged despite 90 days of methylation support at therapeutic doses? Investigate further — CBS variants, B12 absorption issues, COMT interactions, or other pathway disruptions may need addressing. A functional medicine practitioner with methylation expertise is valuable at this juncture.
Food-First Strategies for Methylation Support
Supplements correct deficiencies. Food builds the system. The dietary approach to methylation support focuses on maximizing natural methylfolate intake from food while supporting all cofactors in the cycle through whole food sources. Not instead of supplementation for people with significant variants — in addition to it.
Natural folate sources (all provide methylfolate in food matrix, not synthetic folic acid): lentils (358 mcg per cooked cup), black-eyed peas (358 mcg), spinach (263 mcg per cooked cup), asparagus (268 mcg per cup), avocado (163 mcg per whole fruit), broccoli (168 mcg per cooked cup), Brussels sprouts (156 mcg per cup). A diet centered on legumes and dark leafy greens provides substantial daily folate before any supplementation.
B12 is exclusively from animal products (or fortified foods) — liver (70 mcg per 3oz, over 1,000% RDA), clams (84 mcg per 3oz), sardines (7.6 mcg per 3oz), salmon (3.2 mcg per 3oz), beef (2.4 mcg per 3oz). B6-as-P5P in food: organ meats are the richest source; chickpeas, tuna, salmon, chicken, and bananas provide meaningful amounts. Magnesium from food: pumpkin seeds, dark chocolate, almonds, spinach, black beans.
Choline deserves mention in the methylation context. Choline is an alternative methyl donor — the phosphatidylcholine pathway can provide methyl groups via BHMT enzyme, partially compensating for MTHFR pathway impairment. Clinically significant: adequate choline intake from eggs (egg yolks specifically — each contains ~150 mg choline), liver, seafood, and legumes may meaningfully reduce the functional impact of MTHFR variants by providing an alternative methylation pathway.
Implementing a Methylation Support Protocol Step by Step
The gap between knowing about MTHFR variants and successfully implementing a methylation support protocol is where most people get lost. The theory is clear; the implementation gets complicated by starting dose sensitivities, supplement interactions, and the highly individual nature of methylation chemistry. Here’s a step-by-step implementation guide.
Step 1 — Test before you supplement. Get the MTHFR genotype (C677T and A1298C at minimum) and functional markers (homocysteine, RBC folate, serum B12, methylmalonic acid). Knowing baseline homocysteine is especially important — it tells you whether the body is compensating adequately for whatever variants are present. MTHFR variants without elevated homocysteine may require less aggressive intervention than variants with elevated homocysteine.
Step 2 — Remove folic acid from your environment. Audit every supplement, multivitamin, prenatal vitamin, fortified food, and protein powder consumed. Eliminate or replace anything containing folic acid for anyone carrying significant MTHFR variants. Read labels: “folate” on a label may still be folic acid under the guise of “B9.” Look specifically for “5-methyltetrahydrofolate,” “methylfolate,” “Metafolin,” or “Quatrefolic” as the form.
Step 3 — Start methylfolate low and go slow. The most common mistake in methylation support: starting at high doses immediately. Some people, particularly those with slow COMT variants or histamine intolerance, experience anxiety, irritability, or insomnia when they begin methylfolate. The low-and-slow approach holds at the bottom of the range for two to four weeks before going anywhere. If symptoms show up, the move is to back off rather than stop outright — some methylfolate is still needed — and climb more gradually from there.
Step 4 — Add the cofactors. Methylation doesn’t happen from methylfolate alone. The cycle requires B12 (as methylcobalamin or hydroxocobalamin), B6 (as P5P, which avoids the sensory neuropathy risk that comes with very high-dose pyridoxine), magnesium in the glycinate form, and riboflavin — B2 is required for MTHFR enzyme function and can partially compensate for a reduced-function variant, which is one of the more useful and least discussed facts in this whole area. Zinc supports methionine synthase activity.
Step 5 — Retest homocysteine at 60-90 days. Homocysteine is the feedback metric. Down from 14 to 8? The protocol is working. Unchanged despite 90 days of methylation support at therapeutic doses? Investigate further — CBS variants, B12 absorption issues, COMT interactions, or other pathway disruptions may need addressing. A functional medicine practitioner with methylation expertise is valuable at this juncture.
Food-First Strategies for Methylation Support
Supplements correct deficiencies. Food builds the system. The dietary approach to methylation support focuses on maximizing natural methylfolate intake from food while supporting all cofactors in the cycle through whole food sources. Not instead of supplementation for people with significant variants — in addition to it.
Natural folate sources (all provide methylfolate in food matrix, not synthetic folic acid): lentils (358 mcg per cooked cup), black-eyed peas (358 mcg), spinach (263 mcg per cooked cup), asparagus (268 mcg per cup), avocado (163 mcg per whole fruit), broccoli (168 mcg per cooked cup), Brussels sprouts (156 mcg per cup). A diet centered on legumes and dark leafy greens provides substantial daily folate before any supplementation.
B12 is exclusively from animal products (or fortified foods) — liver (70 mcg per 3oz, over 1,000% RDA), clams (84 mcg per 3oz), sardines (7.6 mcg per 3oz), salmon (3.2 mcg per 3oz), beef (2.4 mcg per 3oz). B6-as-P5P in food: organ meats are the richest source; chickpeas, tuna, salmon, chicken, and bananas provide meaningful amounts. Magnesium from food: pumpkin seeds, dark chocolate, almonds, spinach, black beans.
Choline deserves mention in the methylation context. Choline is an alternative methyl donor — the phosphatidylcholine pathway can provide methyl groups via BHMT enzyme, partially compensating for MTHFR pathway impairment. Clinically significant: adequate choline intake from eggs (egg yolks specifically — each contains ~150 mg choline), liver, seafood, and legumes may meaningfully reduce the functional impact of MTHFR variants by providing an alternative methylation pathway.
The Practical Framework: Applying MTHFR Actually Does In Real Life
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map